BPG is committed to discovery and dissemination of knowledge
Prospective Study
Copyright: ©Author(s) 2026.
World J Cardiol. May 26, 2026; 18(5): 119429
Published online May 26, 2026. doi: 10.4330/wjc.v18.i5.119429
Table 2 Admission biomarkers according to 3-month survival status, median, (interquartile range)
Variable
Survivors (n = 146)
Non-survivors (n = 25)
P value
Age, years66 (58-73)75 (69-82)< 0.001
Admission glucose, (mmol/L)7.20 (6.30-8.50)9.10 (8.10-11.40)0.012
HbA1c (%)6.1 (5.7-7.0)6.2 (5.8-7.2)0.528
Stress hyperglycemia ratio0.90 (0.78-1.05)1.18 (1.02-1.35)0.018
Admission glucose-to-chronic glycemia ratio 0.76 (0.68-0.88)0.99 (0.87-1.12)0.016
C-reactive protein (mg/L)9.0 (4.0-18.0)30.4 (18.0-62.0)< 0.001
Pan-immune-inflammation value 561 (320-980)1399 (850-2100)0.005
Triglyceride-glucose index 8.8 (8.4-9.2)9.0 (8.6-9.4)0.18
Atherogenic index of plasma 0.26 (0.14-0.39)0.29 (0.17-0.41)0.31
De Ritis ratio (AST/ALT)1.12 (0.94-1.34)1.18 (0.97-1.42)0.27


Write to the Help Desk